Xeris Biopharma Holdings, Inc. XERS Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product revenue, net by Product | ||||||
| Gvoke | $94.06M+8.0% | $94.11M+13.6% | $92.73M+18.6% | $90.52M+24.0% | $87.1M+27.0% | |
| Keveyis | $48.11M+0.5% | $47.65M-3.8% | $45.97M-12.4% | $46.23M-17.7% | $47.87M-16.2% | |
| Recorlev | $163.52M+106% | $139.28M+117% | $116.56M+126% | $97.31M+133% | $79.21M+122% | |
| Royalty, contract and other revenue | $7.2M-14.1% | $8.84M+37.4% | $9.56M+83.4% | $10.65M+2.1% | $8.38M-16.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Xeris Biopharma Holdings, Inc. break its business down?
- Xeris Biopharma Holdings, Inc. (XERS) reports product revenue, net by product across 4 parts — Gvoke, Keveyis, Recorlev and Royalty, contract and other revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Xeris Biopharma Holdings, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Xeris Biopharma Holdings, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
